Phase II Study of Gemcitabine and Cisplatin

Trial NCT00003723

Official Title: Phase II Study of Gemcitabine and Cisplatin in Unresectable Malignant Mesothelioma

Rationale: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.

Purpose: Phase II trial to study the effectiveness of gemcitabine plus cisplatin in treating patients with malignant mesothelioma of the pleura that cannot be removed by surgery.


  • Estimate overall survival and confirmed and unconfirmed complete and partial response in patients with unresectable malignant mesothelioma of the pleura treated with gemcitabine plus cisplatin.
  • Evaluate the qualitative and quantitative toxicities of this regimen in this patient population.
  • Eligibility: Male and female mesothelioma patients 18 years of age or older.

Study Design:

  • Primary Purpose: Treatment

Date and Locations:

  • Study Start Date: February 1999


National Institutes of Health